NIH awards $12 million to fund clinical trials for AD vaccine

Biotech company PharmaJet announced that its partner, the Institute for Molecular Medicine, was awarded a $12 million grant from the NIH National Institute on Aging for a vaccine to prevent Alzheimer’s disease.

According to a company press release, the grant will support clinical trials of IMM’s beta-amyloid vaccines based on DNA and recombinant protein, including a phase 1 clinical study in the U.S. that is expected to begin in the second quarter of 2022. The study’s vaccine will be exclusively delivered by PharmaJet’s Tropis needle-free injection system.

“We are pleased to be partnering with IMM in this important clinical trial and adding Alzheimer’s disease to our growing nucleic-acid-based R&D pipeline,” Chris Cappello, president and CEO of PharmaJet, said in the release. “Studies have demonstrated that delivery with the PharmaJet Tropis System has improved vaccine effectiveness.”